Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
about
Interleukin 12: still a promising candidate for tumor immunotherapy?Immunotherapy for colorectal cancerA Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image CytometryHistone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.Present and Future of Allogeneic Natural Killer Cell TherapyClinical utility of natural killer cells in cancer therapy and transplantation.Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma.CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity.Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer.
P2860
Q26861559-5BA332F6-18C2-4912-A8CF-36B5D1327CB2Q27021837-2FFBB2F3-AF7A-4034-904E-16C7E50D044AQ27312227-3591FC84-7C40-4738-929E-886553DE9D60Q34060387-2CC4A793-B700-4686-A975-53A1B17B11F0Q35677351-18EE64EF-BCE8-4FAA-8A1B-96BF73C727E2Q38195120-F6F42E16-4BAB-4C78-B11D-3C1AC2A72CB3Q38260461-82AC2F2B-DB10-402D-A17C-E5507D206C9EQ38945158-D23C8739-D35E-471A-9BD8-582AFCA61A7BQ39281940-36B63B55-9DD8-4392-A695-BCA37DB4B4D9Q40393121-8ACEC86A-23CD-4178-AD7C-E1826D6CD301Q41991684-B92A4DC9-6CE2-436A-B425-6883D6BB5099Q46423964-32E55278-5471-4A83-9639-CEE577512CC6Q47161087-6CD92967-479F-4726-BCDD-DF5958228243Q52655339-75B69E42-22C5-4275-B119-D8238AA0CD9C
P2860
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@en
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@nl
type
label
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@en
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@nl
prefLabel
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@en
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@nl
P2860
P50
P356
P1476
Doxorubicin sensitizes human t ...... nted TRAIL receptor signaling.
@en
P2093
Padraig D'Arcy
Richard Childs
P2860
P304
P356
10.1002/IJC.28163
P50
P577
2013-04-11T00:00:00Z